Degarelix

Extended indication	Degarelix Accord is a gonadotrophin releasing hormone (GnRH) antagonist indicated for treatment of adult male patients with advanced hormone-dependent prostate cancer, for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy and as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
Therapeutic value	Possible equal value
Registration phase	Registered

Product

Active substance	Degarelix
Domain	Oncology
Reason of inclusion	Generic
Main indication	Prostate cancer
Extended indication	Degarelix Accord is a gonadotrophin releasing hormone (GnRH) antagonist indicated for treatment of adult male patients with advanced hormone-dependent prostate cancer, for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy and as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
Current proprietary name	Firmagon (Ferring)
Already available biosimilars / generics	Geen
Manufacturer	Accord Healthcare
Budgetting framework	Extramural (GVS)
Additional remarks	Werkingsmechanisme gonadotrophin releasing hormone (GnRH) antagonist. Fabrikant: Accord Healthcare S.L.U

Therapeutic value	Possible equal value

Patiëntvolume is niet van toepassing bij generieke geneesmiddelen of biosimilars.

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

There is currently nothing known about off label use.

There is currently nothing known about indication extensions.

There is currently no futher information available.